Thursday, 28 March 2024


Schrödinger, WuXi AppTec launch Faxian Therapeutics

01 November 2018 | News

The new venture will leverage the precision molecular design platforms developed by Schrödinger.

Schrödinger, a privately-held company revolutionizing drug discovery through advanced computational methods and enterprise software solutions, and WuXi AppTec, a leading pharmaceutical and medical device R&D enabling platform company, have formed Faxian Therapeutics.  The new venture will leverage the precision molecular design platforms developed by Schrödinger and accelerate them through partnership with the world-class lead optimization services provided by WuXi AppTec.

Headquartered in New York City, Faxian Therapeutics will identify opportunities where new insights into the chemistry and biology of a particular target and indication can be derived using the Schrödinger computational platform, and then uniquely enabled by integration into a rapid design-synthesize-test cycle implemented at WuXi AppTec. 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account